Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Impact of cancer research bureaucracy on innovation, costs, and patient care.

× No keyword cloud information.

14 in total

Review 1. Cancer drug development: The missing links.

Authors: Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal: Exp Biol Med (Maywood) Date: 2019-04-08

2. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.

Authors: Lorenzo Trippa; Patrick Y Wen; Giovanni Parmigiani; Donald A Berry; Brian M Alexander
Journal: Neuro Oncol Date: 2015-01-07 Impact factor: 12.300

3. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.

Authors: Mark C Markowski; Kevin D Frick; James R Eshleman; Jun Luo; Emmanuel S Antonarakis
Journal: Prostate Date: 2016-07-12 Impact factor: 4.104

4. PACE Continuous Innovation Indicators-a novel tool to measure progress in cancer treatments.

Authors: Silvia Paddock; Lauren Brum; Kathleen Sorrow; Samuel Thomas; Susan Spence; Catharina Maulbecker-Armstrong; Clifford Goodman; Michael Peake; Gordon McVie; Gary Geipel; Rose Li
Journal: Ecancermedicalscience Date: 2015-01-07

5. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.

Authors: Jacob J Mandel; Shlomit Yust-Katz; Akash J Patel; David Cachia; Diane Liu; Minjeong Park; Ying Yuan; Thomas A Kent; John F de Groot
Journal: Neuro Oncol Date: 2018-01-10 Impact factor: 12.300

6. The Signature Program: Bringing the Protocol to the Patient.

Authors: B P Kang; E Slosberg; S Snodgrass; C Lebedinsky; D A Berry; C L Corless; S Stein; A Salvado
Journal: Clin Pharmacol Ther Date: 2015-05-11 Impact factor: 6.875

7. Activating clinical trials: a process improvement approach.

Authors: Diego A Martinez; Athanasios Tsalatsanis; Ali Yalcin; José L Zayas-Castro; Benjamin Djulbegovic
Journal: Trials Date: 2016-02-24 Impact factor: 2.279

8. Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.

Authors: Stella Erdmann; Marietta Kirchner; Heiko Götte; Meinhard Kieser
Journal: BMC Med Res Methodol Date: 2020-10-09 Impact factor: 4.615

Review 9. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy.

Authors: Jose Luis Perez-Gracia; Ahmad Awada; Emiliano Calvo; Teresa Amaral; Hendrik-Tobias Arkenau; Viktor Gruenwald; Gyorgy Bodoky; Martijn P Lolkema; Massimo Di Nicola; Nicolas Penel; Ruth Vera; Miguel F Sanmamed; Jean-Yves Douillard
Journal: ESMO Open Date: 2020-05

10. Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms.

Authors: Kamal S Saini; Begoña de Las Heras; Ruth Plummer; Victor Moreno; Marco Romano; Javier de Castro; Philippe Aftimos; Judy Fredriksson; Gouri Shankar Bhattacharyya; Martin Sebastian Olivo; Gaia Schiavon; Kevin Punie; Jesus Garcia-Foncillas; Ernesto Rogata; Richie Pfeiffer; Cecilia Orbegoso; Kenneth Morrison; Giuseppe Curigliano; Lynda Chin; Monika Lamba Saini; Øystein Rekdal; Steven Anderson; Javier Cortes; Manuela Leone; Janet Dancey; Chris Twelves; Ahmad Awada
Journal: JCO Glob Oncol Date: 2020-09